Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy DOI Open Access
Ying Chen, Ao Zhang,

Jing-Rong Wang

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1588 - 1588

Published: May 7, 2025

Lung cancer brain metastasis (LCBM) is a major contributor to cancer-related mortality, with median survival of 8–16 months following diagnosis, despite advances in therapeutic strategies. The development clinically relevant animal models crucial for understanding the metastatic cascade and assessing therapies that can penetrate blood–brain barrier (BBB). This review critically evaluates five primary LCBM modeling approaches—orthotopic implantation, intracardiac injection, stereotactic intracranial carotid artery tail vein injection—focusing on their clinical applicability. We systematically compare ability replicate human pathophysiology highlight emerging technologies personalized therapy screening. Additionally, we analyze breakthrough strategies central nervous system (CNS)-targeted drug delivery, including microparticle targeted delivery systems designed enhance accumulation. By incorporating single-cell omics AI-driven prediction, this work provides roadmap next generation models, aimed at bridging preclinical research.

Language: Английский

Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis DOI
Luke Pike, Helena A. Yu, Chad G. Rusthoven

et al.

JAMA Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

This clinical evidence synopsis summarizes the results of 3 multi-institutional cohort studies that compare tyrosine kinase inhibitors with or without stereotactic radiosurgery in patients non–small cell lung cancer brain metastases.

Language: Английский

Citations

0
Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy DOI Open Access
Ying Chen, Ao Zhang,

Jing-Rong Wang

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1588 - 1588

Published: May 7, 2025

Lung cancer brain metastasis (LCBM) is a major contributor to cancer-related mortality, with median survival of 8–16 months following diagnosis, despite advances in therapeutic strategies. The development clinically relevant animal models crucial for understanding the metastatic cascade and assessing therapies that can penetrate blood–brain barrier (BBB). This review critically evaluates five primary LCBM modeling approaches—orthotopic implantation, intracardiac injection, stereotactic intracranial carotid artery tail vein injection—focusing on their clinical applicability. We systematically compare ability replicate human pathophysiology highlight emerging technologies personalized therapy screening. Additionally, we analyze breakthrough strategies central nervous system (CNS)-targeted drug delivery, including microparticle targeted delivery systems designed enhance accumulation. By incorporating single-cell omics AI-driven prediction, this work provides roadmap next generation models, aimed at bridging preclinical research.

Language: Английский

Citations

0